Navigation Links
Bionovo's Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
Date:6/16/2008

- Results Presented at Endocrine Society 90th Annual Meeting -

SAN FRANCISCO and EMERYVILLE, Calif., June 16 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI) today announced results from in vitro studies in neurons of its drug candidate, MF101. The data were presented at the Endocrine Society 90th Annual Meeting. Bionovo showed that, in neurons differentiated from mouse stem cells and expressing native estrogen receptors, MF101, an estrogen receptor beta selective modulator, regulated calcium levels, which are related to temperature regulation.

"Menopausal hot flashes occur in approximately 80% of menopausal women," said Dr. Dale Leitman, from the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California, San Francisco. "It has long been known that estrogens reduce hot flashes and non-selective SERMs cause hot flashes. However, there have not been appropriate cell-based models to screen estrogens for effects on neurons. This study demonstrated that changes in calcium levels in neurons, an important biochemical pathway to temperature regulation, are mediated selectively by the activation of estrogen receptor beta. MF101 demonstrated this selective regulation."

The study was conducted by investigators at The Center for Reproductive Sciences in the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California, San Francisco in collaboration with scientists at Bionovo.

"Although estrogens are very effective in the treatment of menopausal hot flashes, they have been associated with many serious health risks, such as breast and uterine cancer," said Isaac Cohen, Bionovo's chairman and chief executive officer. "In a Phase 2 clinical trial, MF101, our selective estrogen receptor beta modulator, was effective in the treatment of hot flashes. But unlike estrogen, it did not adversely effect the uterus. This study provides a further mechanistic explanation to the observed clinical results. We believe that the efficacy coupled with improved safety of MF101 over current estrogen treatment will be greatly welcomed by women going through menopause. The results also demonstrate Bionovo's robust science for its pipeline under development for women's health."

About MF101

MF101 is an estrogen receptor beta (ER-b) selective drug for the treatment of menopausal hot flashes, developed as an alternative to those products currently on the market, which have been shown to increase the risk for breast and uterine cancers. It has been shown that the increased risk of breast and uterine cancers is associated with estrogen receptor alpha (ER-a) activation and that estrogen receptor beta (ER-b) blocks the growth promoting effects on breast cancer cells. Bionovo recognized the opportunity to commercialize a product that would be equally effective, with an improved safety profile to hormone therapy. The drug candidate has been evaluated by an independent Data and Safety Monitoring Board and has passed through a standard two-round examination for safety.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, which are markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
3. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
7. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
8. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
9. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. Leading AIDS Groups Turn Up The Heat on 08 Presidential Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 ... platform, the first non-viral gene expression technology that enables ... the eye to address a wide range of ophthalmic ... Medicines and Healthcare products Regulatory Agency (MHRA) to advance ... ...
(Date:4/19/2017)... 2017 The Mobile X-Ray product segment is the ... during the forecast period Mobile X-Ray segment is ... mobile X-Ray devices market, which is estimated to be valued ... a CAGR of 7% over the forecast period. Mobile X-Ray ... than US$ 100 Mn in 2017 over 2016. The segment,s ...
(Date:4/19/2017)... 19, 2017 The Global Effective Microorganisms ... 2022 report has covered and analysed the potential of Global ... market size, shares and growth factors. The report identifies and ... opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... From April 30 to ... Care Medicine will host industry leaders for the annual spring Convention & Expo, ... the industry adapt to the issues currently affecting urgent care and on-demand healthcare. ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... a pilot study of ActiGraph’s CentrePoint Data Hub in a sample ... provider of clinical-grade wearable activity and sleep monitoring solutions for the global scientific ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor that has ... presence to an educational purpose as the host of the “Informed” series. The program ... a recent episode, the series focuses on thyroid cancer. , Although thyroid cancer is ...
(Date:4/27/2017)... ... April 27, 2017 , ... Healthcare companies are trying to meet ... reject an outdated healthcare executive resume. , “If you’re a healthcare executive open to ... and wondering if it’s as ready as you are for a new job search. ...
(Date:4/27/2017)... ... 2017 , ... Goodcents Deli Fresh Subs announced a franchise expansion agreement today ... , The first new location will open at the corner of 27th and ... Northern Lights Drive this fall. And the third location is in the process of ...
Breaking Medicine News(10 mins):